Taxanes in breast cancer: An update
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/BF02951422.pdf
Reference53 articles.
1. Seidman AD, Tiersten A, Hudis C, et al.:Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.J Clin Oncol 1995,13:2575–2581.
2. Chan S, Friedrichs K, Noel D, et al.:Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.J Clin Oncol 1999,17:2341.
3. Sledge GW Jr, Neuberg D, Bernardo P, et al.:Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193).J Clin Oncol 2003,21:588–592.
4. Bishop JF, Denwar J, Toner GC, et al.:Initial paclitaxel improves outcome compared to CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer.J Clin Oncol 1999,17:2355–2364.
5. Mamounas EP, Bryant J, Lembersky B, et al.:Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.J Clin Oncol 2005,23:3686–3696.
Cited by 43 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Duloxetine to prevent neuropathy in breast cancer patients under paclitaxel chemotherapy (a double-blind randomized trial);Supportive Care in Cancer;2024-07-08
2. Polysorbate 80 as a possible allergenic component in cross-allergy to docetaxel and fosaprepitant: A literature review;Journal of Oncology Pharmacy Practice;2023-10-11
3. Molecular Biology Mechanisms and Emerging Therapeutics of Triple-Negative Breast Cancer;Biologics: Targets and Therapy;2023-09
4. Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses;Cancers;2023-04-21
5. Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results;The Breast;2023-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3